PMID- 29728800
OWN - NLM
STAT- MEDLINE
DCOM- 20190625
LR  - 20190625
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 82
IP  - 1
DP  - 2018 Jul
TI  - Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin 
      followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung 
      cancer.
PG  - 111-117
LID - 10.1007/s00280-018-3598-4 [doi]
AB  - PURPOSE: We conducted a phase II trial to evaluate the efficacy and safety of 
      induction chemotherapy of pemetrexed plus split-dose cisplatin followed by 
      pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer 
      (NSCLC). METHODS: Patients with advanced or recurrent untreated non-squamous 
      NSCLC received split-dose cisplatin (40 mg/m(2), days 1 and 8) plus pemetrexed 
      (500 mg/m(2), day 1) tri-weekly. After four cycles of induction, patients without 
      disease progression received pemetrexed maintenance until disease progression or 
      unacceptable toxicity. The primary endpoint was the 1-year survival rate. The 
      secondary endpoints were progression-free survival (PFS), overall survival (OS), 
      response in induction phase, and safety. RESULTS: From February 2012 to September 
      2014, 53 assessable patients were enrolled in this study. Thirty-eight (71.7%) 
      patients completed induction therapy, while 35 (66.0%) received maintenance 
      therapy. The 1-year survival rate was 67.7%. The median PFS and OS were 5.3 and 
      18.6 months, respectively. The response rate and disease control rate (DCR) 
      during the induction phase were 37.7 and 86.8%, respectively. Eight patients 
      (15.1%) discontinued the therapy due to adverse events (AEs) during the induction 
      phase, but both hematological and non-hematological AEs were infrequent. 
      CONCLUSIONS: Treatment with induction chemotherapy of pemetrexed plus split-dose 
      cisplatin showed a promising 1-year survival rate, DCR, and transition rate into 
      maintenance phase. This regimen is feasible and well-tolerated. A phase III study 
      comparing this regimen with conventional tri-weekly regimen is warranted.
FAU - Koba, Taro
AU  - Koba T
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka, Osaka, 543-0035, Japan.
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University 
      Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
FAU - Minami, Seigo
AU  - Minami S
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka, Osaka, 543-0035, Japan.
FAU - Nishijima-Futami, Yu
AU  - Nishijima-Futami Y
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka, Osaka, 543-0035, Japan.
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University 
      Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
FAU - Masuhiro, Kentaro
AU  - Masuhiro K
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka, Osaka, 543-0035, Japan.
AD  - Department of Thoracic Malignancy, Osaka Habikino Medical Center, 3-7-1 Habikino, 
      Habikino, 583-8588, Japan.
FAU - Kimura, Hiromi
AU  - Kimura H
AD  - Department of Thoracic Oncology, National Hospital Organization Toneyama National 
      Hospital, 5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan.
AD  - Department of Internal Medicine, Osaka Hospital Anti-Tuberculosis Association, 
      2276-1 Neyagawa-kouen, Neyagawa, Osaka, 572-0854, Japan.
FAU - Futami, Shinji
AU  - Futami S
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka, Osaka, 543-0035, Japan.
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University 
      Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
FAU - Yaga, Moto
AU  - Yaga M
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka, Osaka, 543-0035, Japan.
AD  - Department of Respiratory Medicine, NTT West Osaka Hospital, 2-6-40 
      Karasugatsuji, Tennoji-ku, Osaka, Osaka, 543-8922, Japan.
FAU - Mori, Masahide
AU  - Mori M
AD  - Department of Thoracic Oncology, National Hospital Organization Toneyama National 
      Hospital, 5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan.
FAU - Kagawa, Hiroyuki
AU  - Kagawa H
AD  - Department of Thoracic Oncology, National Hospital Organization Toneyama National 
      Hospital, 5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan.
FAU - Uenami, Takeshi
AU  - Uenami T
AD  - Department of Thoracic Oncology, National Hospital Organization Toneyama National 
      Hospital, 5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan.
FAU - Kohmo, Satoshi
AU  - Kohmo S
AD  - Department of General Internal Medicine, Nissay Hospital, 6-3-8 Itachibori, 
      Nishi-ku, Osaka, Osaka, 550-0012, Japan.
FAU - Otsuka, Tomoyuki
AU  - Otsuka T
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University 
      Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
AD  - Department of Thoracic Oncology, National Hospital Organization Toneyama National 
      Hospital, 5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan.
AD  - Department of Medical Oncology, Osaka International Cancer Institute, 3-1-69 
      Otemae, Chuo-ku, Oska, Osaka, 541-8567, Japan.
FAU - Yamamoto, Suguru
AU  - Yamamoto S
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka, Osaka, 543-0035, Japan.
FAU - Komuta, Kiyoshi
AU  - Komuta K
AD  - Department of Respiratory Medicine, Osaka Police Hospital, 10-31 Kitayama-cho, 
      Tennoji-ku, Osaka, Osaka, 543-0035, Japan.
FAU - Kijima, Takashi
AU  - Kijima T
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University 
      Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan. 
      tkijima@hyo-med.ac.jp.
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College 
      of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. 
      tkijima@hyo-med.ac.jp.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20180504
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Induction Chemotherapy
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*drug therapy
MH  - Maintenance Chemotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy
MH  - Pemetrexed/administration & dosage/adverse effects
MH  - Progression-Free Survival
OTO - NOTNLM
OT  - Maintenance therapy
OT  - Multi-centered
OT  - Non-squamous non-small-cell lung cancer
OT  - Pemetrexed
OT  - Phase 2 trial
OT  - Split-dose cisplatin
EDAT- 2018/05/08 06:00
MHDA- 2019/06/27 06:00
CRDT- 2018/05/06 06:00
PHST- 2017/12/19 00:00 [received]
PHST- 2018/05/01 00:00 [accepted]
PHST- 2018/05/08 06:00 [pubmed]
PHST- 2019/06/27 06:00 [medline]
PHST- 2018/05/06 06:00 [entrez]
AID - 10.1007/s00280-018-3598-4 [pii]
AID - 10.1007/s00280-018-3598-4 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2018 Jul;82(1):111-117. doi: 
      10.1007/s00280-018-3598-4. Epub 2018 May 4.